IFRS 17
Learn moreSolvency II
Learn moreInsight from Milliman
Cost and Effectiveness of Lung Cancer Screening in Poland: a 15-year projection
Lung cancer screening programs yield substantial improvements in outcomes, with our analysis estimating an increase of 3.74 life years per cancer case in Poland.
Extreme weather events in Europe
Our extensive research helps European insurers understand the scale of last year's drought, heat waves, and floods —and anticipate what business decisions could lie ahead.
Global life and health insurance mergers and acquisitions
Get a breakdown of top M&A deals and an overview of market trends in North America, Europe, Asia, and Latin America.
Consistent equity risk-neutral valuation under climate stress tests
With a proper granularity of modeling, shocks prescribed by European regulators related to climate transition risk can be applied to estimate ALM impacts.
Challenges and opportunities for CEE insurers in the “Brave New World” of higher interest rates
The radical change in the interest rate environment has many implications for CEE insurers, presenting challenges and opportunities not seen for years.
MTPL markets in CEE
We look at the MTPL markets of four Central-Eastern European countries, characterized by growing societal wealth and motor vehicle use.
Developing climate risk scenarios for Solvency II ORSA
European insurers face challenges in the assessment of transition risks on assets for climate risk scenarios under Solvency II ORSA.
Bridging the insurance gap: A global challenge for financial resilience
To bridge the insurance gap that leaves millions of people vulnerable, governments, insurance companies and international organizations need to work together.
How might IFRS 17 change European insurance M&A?
While we don’t expect IFRS 17 to fundamentally change insurance mergers and acquisitions in the short term, European insurers will likely increasingly focus on results over time.